Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Sulfa	O
(Sulfonamide	O
Antibiotics)	O
/	O
vancomycin	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Dyspnea	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
Chest	O
Tube	O
placement	O
and	O
removal.	O
History	O
of	O
Present	O
Illness:	O
___	O
is	O
a	O
___	O
year	O
old	O
woman	O
with	O
low	O
grade	O
follicular	O
lymphoma,	O
currently	O
on	O
oxbinutuzumab	O
admitted	O
with	O
several	O
weeks	O
of	O
progressive	O
shortness	O
of	O
breath	O
and	O
cough.	O
Starting	O
in	O
mid	O
___,	O
patient	O
developed	O
symptoms	O
of	O
severe	O
coughing.	O
She	O
had	O
associated	O
rhinitis	O
but	O
no	O
other	O
significant	O
symptoms.	O
Her	O
cough	O
progressed	O
to	O
the	O
point	O
she	O
developed	O
marked	O
right	O
chest	O
rib	O
pain.	O
She	O
started	O
a	O
course	O
of	O
azithromycin	O
on	O
___	O
and	O
was	O
seen	O
in	O
___	O
clinic	O
on	O
___.	O
She	O
appeared	O
relatively	O
well	O
at	O
the	O
time	O
and	O
she	O
was	O
treated	O
supportively	O
with	O
benzonatate.	O
Despite	O
the	O
benzonatate	O
and	O
azithromycin,	O
her	O
cough	O
and	O
pain	O
progressed	O
significantly	O
over	O
the	O
last	O
week.	O
She	O
now	O
has	O
associated	O
fatigue,	O
and	O
on	O
day	O
of	O
admission	O
it	O
got	O
to	O
the	O
point	O
she	O
'couldn't	O
move',	O
so	O
she	O
presented	O
to	O
the	O
ED.	O
In	O
the	O
ED,	O
initial	O
VS	O
were	O
T	O
98.2,	O
HR	O
82,	O
BP	O
126/70.	O
Pain	O
intermittently	O
rated	O
between	O
0	O
and	O
10.	O
She	O
was	O
initially	O
noted	O
to	O
be	O
in	O
significant	O
respiratory	O
distress	O
and	O
placed	O
on	O
a	O
NRB.	O
Initial	O
labs	O
notable	O
for	O
Na	O
134,	O
K	O
7.4	O
(hemolyzed,	O
repeat	O
5.0),	O
HCO3	O
22,	O
Cr	O
0.6,	O
lactate	O
1.8,	O
ABG	O
7.49/___,	O
WBC	O
9.1	O
(89%N).	O
CXR	O
showed	O
RLL	O
consdildation	O
and	O
pleural	O
effusion	O
c/w	O
PNA.	B-Lower_respiratory_tract_infection
Patient	O
was	O
given	O
duonebs	O
x2,	O
IV	O
ketorolac,	O
and	O
1g	O
IV	O
CTX,	O
and	O
tramadol	O
prior	O
to	O
transfer	O
for	O
further	O
management.	O
VS	O
prior	O
to	O
transfer	O
were	O
HR	O
92,	O
BP	O
101/48,	O
RR	O
26,	O
O2	O
96%2LNC.	O
On	O
arrival	O
to	O
the	O
floor,	O
patient	O
reports	O
severe	O
paroxysms	O
of	O
cough	O
with	O
right	O
sided	O
chest	O
pain	O
and	O
abdominal	O
muscle	O
soreness.	O
Also	O
with	O
rhinitis.	O
She	O
denies	O
frank	O
shortness	O
of	O
breath,	O
but	O
note	O
she	O
has	O
to	O
'pant'	O
to	O
prevent	O
coughing	O
fits	O
and	O
pain.	O
No	O
fevers	O
or	O
chills.	O
No	O
headaches.	O
Did	O
develop	O
a	O
sore	O
in	O
her	O
mouth	O
while	O
taking	O
azithromycin	O
and	O
also	O
recently	O
cracked	O
a	O
tooth.	O
No	O
N/V	O
or	O
frank	O
abdominal	O
pain.	O
No	O
diarrhea.	O
No	O
dysuria.	O
No	O
new	O
leg	O
pain	O
or	O
swelling.	O
Past	O
Medical	O
History:	O
PAST	O
ONCOLOGIC	O
HISTORY	O
-	O
per	O
Dr.	O
___	O
note	O
in	O
___	O
HISTORY	O
OF	O
PRESENT	O
ILLNESS:	O
Ms.	O
___	O
is	O
a	O
___	O
woman	O
with	O
a	O
longstanding	O
history	O
of	O
follicular	O
lymphoma	O
dating	O
back	O
to	O
___.	O
She	O
was	O
initially	O
treated	O
with	O
Rituxan	O
along	O
with	O
fludarabine	O
which	O
was	O
then	O
followed	O
by	O
CVP	O
with	O
Zevalin	O
given	O
in	O
___.	O
She	O
continued	O
on	O
maintenance	O
rituximab	O
until	O
___.	O
In	O
___,	O
she	O
began	O
showing	O
circulating	O
lymphocytes	O
and	O
increasing	O
LDH	O
with	O
concern	O
for	O
a	O
poor	O
response	O
to	O
Rituxan	O
and	O
she	O
subsequently	O
then	O
received	O
treatment	O
with	O
bendamustine	O
in	O
___	O
and	O
completed	O
three	O
cycles	O
of	O
treatment	O
as	O
of	O
___.	O
Her	O
treatment	O
was	O
put	O
on	O
hold	O
as	O
she	O
was	O
dealing	O
with	O
issues	O
around	O
squamous	O
cell	O
carcinoma.	O
She	O
has	O
received	O
Rituxan	O
periodically	O
since	O
that	O
time	O
when	O
she	O
was	O
noted	O
for	O
increasing	O
LDH	O
and	O
atypical	O
cells.	O
Her	O
last	O
treatment	O
with	O
Rituxan	O
was	O
in	O
___.	O
Starting	O
in	O
___,	O
Ms.	O
___	O
was	O
noted	O
for	O
increasing	O
nodes	O
in	O
the	O
left	O
neck	O
adenopathy.	O
Imaging	O
was	O
done,	O
which	O
showed	O
increased	O
adenopathy	O
within	O
the	O
neck	O
area	O
with	O
a	O
large	O
left	O
cervical	O
rim-enhancing	O
collection	O
noted,	O
with	O
additional	O
large	O
necrotic	O
cervical	O
lymph	O
nodes	O
throughout	O
the	O
left	O
cervical	O
chain.	O
CT	O
of	O
the	O
chest,	O
abdomen	O
and	O
pelvis	O
showed	O
supraclavicular	O
and	O
axillary	O
lymphadenopathy,	O
which	O
had	O
not	O
changed	O
significantly	O
as	O
well	O
as	O
some	O
small	O
retroperitoneal	O
adenopathy	O
and	O
inguinal	O
adenopathy,	O
which	O
had	O
remained	O
relatively	O
stable.	O
Because	O
of	O
the	O
concern	O
for	O
infection	O
vs.	O
transformation	O
of	O
her	O
lymphoma	O
in	O
the	O
neck	O
area,	O
she	O
was	O
sent	O
to	O
the	O
emergency	O
room	O
where	O
attempts	O
at	O
a	O
fine	O
needle	O
aspirate	O
were	O
done.	O
Unfortunately,	O
this	O
was	O
a	O
nondiagnostic	O
procedure	O
and	O
she	O
subsequently	O
underwent	O
a	O
core	O
needle	O
biopsy	O
after	O
being	O
admitted.	O
Review	O
of	O
biopsy	O
results	O
showed	O
a	O
concern	O
for	O
transformation	O
to	O
diffuse	O
large	O
B-cell	O
lymphoma	O
within	O
this	O
lymph	O
node,	O
although	O
it	O
was	O
not	O
an	O
ideal	O
specimen	O
with	O
some	O
crush	O
artifacts.	O
The	O
Ki-67%	O
was	O
lower	O
than	O
that	O
was	O
expected	O
based	O
on	O
the	O
appearance	O
of	O
the	O
lymphocytes	O
in	O
this	O
specimen.	O
It	O
is	O
felt	O
to	O
be	O
better	O
characterized	O
as	O
aggressive	O
lymphoma;	O
cytogenetics	O
could	O
not	O
be	O
run	O
on	O
the	O
specimen.	O
Ms.	O
___	O
decided	O
to	O
pursue	O
treatment	O
with	O
Obinutuzumab.	O
Ideally,	O
we	O
would	O
include	O
Bendamustine	O
with	O
this	O
treatment,	O
but	O
she	O
remains	O
concerned	O
about	O
other	O
side	O
effects	O
including	O
hair	O
loss.	O
She	O
underwent	O
C1D1	O
obinutuzumab	O
on	O
___	O
with	O
C1D2	O
on	O
___.	O
C1D8	O
was	O
held	O
on	O
___.	O
She	O
received	O
XRT	O
to	O
the	O
left	O
neck	O
and	O
supraclavicular	O
area.	O
This	O
completed	O
on	O
___.	O
-	O
___	O
C2	O
Obinutuzumab	O
-	O
___	O
C3	O
Obinutuzumab	O
-	O
___	O
C4	O
Obinutuzumab	O
-	O
___	O
C5	O
Obinutuzumab	O
PAST	O
MEDICAL	O
HISTORY:	O
-	O
Follicular	O
lymphoma,	O
as	O
above	O
-	O
Remote	O
history	O
of	O
pericarditis	O
Social	O
History:	O
___	O
Family	O
History:	O
Her	O
sister	O
has	O
a	O
history	O
of	O
HTN	O
but	O
no	O
other	O
reported	O
chronic	O
diseases.	O
No	O
known	O
family	O
history	O
of	O
malignancy.	O
Physical	O
Exam:	O
VS:	O
T	O
98.3	O
BP	O
102/66	O
HR	O
81	O
RR	O
18	O
O2	O
99%RA	O
General:	O
NAD	O
HEENT:	O
EOMI,	O
MMM,	O
neck	O
supple	O
CV:	O
RRR	O
Lungs:	O
Decreased	O
breath	O
sounds.	O
Chest	O
Tube	O
site	O
with	O
mild	O
tenderness	O
to	O
palpation,	O
no	O
erythema.	O
Abdomen:	O
Soft	O
NT	O
ND	O
Extremities:	O
No	O
edema	O
Neuro:	O
Alert	O
and	O
oriented,	B-Delirium
no	O
focal	O
deficits.	O
Pertinent	O
Results:	O
___	O
04:45PM	O
BLOOD	O
WBC-8.2	O
RBC-2.96*	O
Hgb-9.8*	O
Hct-30.8*	O
MCV-104*	O
MCH-33.1*	O
MCHC-31.8*	O
RDW-13.4	O
RDWSD-50.9*	O
Plt	O
___	O
___	O
03:30PM	O
BLOOD	O
WBC-18.5*	O
RBC-2.53*	O
Hgb-8.5*	O
Hct-25.9*	O
MCV-102*	O
MCH-33.6*	O
MCHC-32.8	O
RDW-13.6	O
RDWSD-51.1*	O
Plt	O
___	O
___	O
06:30AM	O
BLOOD	O
WBC-3.7*	O
RBC-2.18*	O
Hgb-7.2*	O
Hct-22.4*	O
MCV-103*	O
MCH-33.0*	O
MCHC-32.1	O
RDW-13.0	O
RDWSD-48.5*	O
Plt	O
Ct-90*	O
___	O
06:40AM	O
BLOOD	O
___	O
PTT-35.2	O
___	O
___	O
04:45PM	O
BLOOD	O
UreaN-11	O
Creat-0.5	O
___	O
06:30AM	O
BLOOD	O
Glucose-95	O
UreaN-5*	O
Creat-0.4	O
Na-140	O
K-4.4	O
Cl-101	O
HCO3-31	O
AnGap-8	O
___	O
04:45PM	O
BLOOD	O
ALT-15	O
AST-25	O
LD(LDH)-173	O
AlkPhos-121*	O
TotBili-0.3	O
___	O
07:25AM	O
BLOOD	O
Calcium-7.9*	O
Phos-3.5	O
Mg-1.8	O
___	O
06:30AM	O
BLOOD	O
Calcium-7.8*	O
Phos-2.9	O
Mg-2.0	O
Chest	O
CTA	O
___:	O
1.	O
No	O
evidence	O
of	O
pulmonary	O
embolism.	O
2.	O
Multifocal	O
pneumonia.	B-Lower_respiratory_tract_infection
Moderate	O
partially	O
loculated	O
right	O
pleural	O
effusion,	O
and	O
while	O
there	O
is	O
no	O
pleural	O
enhancement	O
which	O
could	O
be	O
from	O
immunocompromised	O
state,	O
empyema	B-Lower_respiratory_tract_infection
could	O
have	O
this	O
appearance	O
and	O
should	O
be	O
excluded.	O
3.	O
Small	O
enhancing	O
mediastinal	O
lymph	O
and	O
hilar	O
nodes	O
are	O
probably	O
reactive.	O
4.	O
Component	O
of	O
right	O
basilar	O
atelectasis.	O
Significant	O
mucous	O
plugging	O
right	O
base.	O
5.	O
Moderate	O
calcified	O
coronary	O
atherosclerosis.	O
6.	O
Probably	O
moderate	O
central	O
canal	O
narrowing	O
lower	O
thoracic	O
spine	O
with	O
calcified	O
disc	O
protrusion.	O
Chest	O
CT	O
___:	O
Multifocal	O
and	O
consolidations	O
improved	O
in	O
the	O
right	O
lower	O
lobe.	O
Decrease	O
in	O
size	O
in	O
small	O
right	O
pleural	O
effusion.	O
Small	O
left	O
pleural	O
effusion	O
has	O
minimally	O
increased.	O
Coronary	O
calcifications	O
Chest	O
X-ray	O
___:	O
1.	O
Small	O
right	O
basilar	O
pneumothorax	O
with	O
adjacent	O
atelectasis	O
is	O
unchanged	O
following	O
chest	O
tube	O
removal.	O
2.	O
Small	O
pleural	O
effusions	O
are	O
unchanged.	O
Brief	O
Hospital	O
Course:	O
___	O
year	O
old	O
woman	O
with	O
low	O
grade	O
follicular	O
lymphoma,	O
currently	O
on	O
oxbinutuzumab	O
who	O
was	O
admitted	O
with	O
several	O
weeks	O
of	O
progressive	O
shortness	O
of	O
breath	O
and	O
cough.	O
Pneumonia	B-Lower_respiratory_tract_infection
-	O
Patient	O
with	O
radiologic	O
evidence	O
of	O
PNA	B-Lower_respiratory_tract_infection
in	O
setting	O
of	O
progressive	O
cough	O
and	O
low	O
grade	O
temperature	O
on	O
arrival.	O
Subsequently	O
developed	O
documented	O
fevers	O
and	O
leukocytosis.	O
Treated	O
as	O
HCAP	B-Lower_respiratory_tract_infection
with	O
linezolid/cefepime/levofloxacin.	O
Also	O
given	O
symptomatic	O
treatment	O
with	O
tessalon	O
and	O
guafenesin.	O
Also	O
with	O
empyema,	O
IP	O
placed	O
chest	O
tube	O
on	O
___	O
and	O
subsequently	O
TPA'd	O
for	O
three	O
days/doses.	O
She	O
did	O
have	O
a	O
decrease	O
in	O
her	O
hemoglobin	O
that	O
may	O
have	O
been	O
due	O
to	O
a	O
pleural	O
reaction	O
from	O
TPA	O
but	O
it	O
stabilized	O
without	O
intervention.	O
Chest	O
tube	O
removed	O
on	O
___.	O
Transitioned	O
to	O
PO	O
augmentin	O
on	O
discharge	O
to	O
complete	O
a	O
four	O
week	O
course	O
per	O
recommendation	O
of	O
interventional	O
pulmonology.	O
She	O
will	O
follow	O
up	O
with	O
IP	O
as	O
an	O
outpatient.	O
Diarrhea	O
-	O
C.diff	O
was	O
negative.	O
Likely	O
side	O
effect	O
of	O
antibiotics.	O
Advised	O
to	O
stay	O
well	O
hydrated.	O
Imodium	O
PRN.	O
Tachycardia	O
-	O
Brief.	O
Likely	O
due	O
to	O
dehydration	O
from	O
poor	O
PO	O
intake.	O
Resolved	O
with	O
IV	O
fluids.	O
Follicular	O
Lymphoma	O
-	O
Due	O
for	O
treatment	O
with	O
obinutuzumab	O
but	O
on	O
hold	O
due	O
to	O
current	O
infection.	O
Will	O
follow	O
up	O
with	O
primary	O
oncologist	O
an	O
outpatient.	O
Did	O
have	O
occasional	O
nausea,	O
given	O
Zofran	O
PRN.	O
She	O
was	O
given	O
IVIG	O
due	O
to	O
low	O
levels	O
and	O
acute	O
infection.	O
Greater	O
than	O
30	O
minutes	O
spent	O
discharge	O
planning.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
___	O
is	O
accurate	O
and	O
complete.	O
1.	O
Clobetasol	O
Propionate	O
0.05%	O
Cream	O
1	O
Appl	O
TP	O
BID:PRN	O
eczema	O
2.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q24H	O
3.	O
Ibuprofen	O
400	O
mg	O
PO	O
Q8H:PRN	O
Pain	O
-	O
Moderate	O
4.	O
biotin	O
1	O
mg	O
oral	O
DAILY	O
5.	O
Digestive	O
Advantage	O
(Bacillus	O
coagulans)	O
250	O
million	O
cell	O
oral	O
DAILY	O
6.	O
evening	O
primrose	O
oil	O
500	O
mg	O
oral	O
DAILY	O
7.	O
Glucosamine	O
1500	O
Complex	O
(glucosamine-chondroit-vit	O
C-Mn)	O
500-400	O
mg	O
oral	O
DAILY	O
Discharge	O
Medications:	O
1.	O
Acetaminophen	O
650	O
mg	O
PO	O
Q6H:PRN	O
Pain	O
-	O
Mild	O
2.	O
Amoxicillin-Clavulanic	O
Acid	O
___	O
mg	O
PO	O
Q12H	O
RX	O
*amoxicillin-pot	O
clavulanate	O
875	O
mg-125	O
mg	O
1	O
tab	O
by	O
mouth	O
every	O
twelve	O
(12)	O
hours	O
Disp	O
#*39	O
Tablet	O
Refills:*0	O
3.	O
Benzonatate	O
200	O
mg	O
PO	O
TID:PRN	O
Cough	O
RX	O
*benzonatate	O
200	O
mg	O
1	O
capsule(s)	O
by	O
mouth	O
three	O
times	O
a	O
day	O
Disp	O
#*30	O
Capsule	O
Refills:*0	O
4.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID:PRN	O
Constipation	B-Constipation
5.	O
Guaifenesin-Dextromethorphan	O
5	O
mL	O
PO	O
Q6H:PRN	O
Cough	O
RX	O
*dextromethorphan-guaifenesin	O
100	O
mg-10	O
mg/5	O
mL	O
5	O
mL	O
by	O
mouth	O
every	O
six	O
(6)	O
hours	O
Refills:*0	O
6.	O
LOPERamide	O
2	O
mg	O
PO	O
QID:PRN	O
Diarrhea	O
7.	O
Ondansetron	O
8	O
mg	O
PO	O
Q8H:PRN	O
Nausea	O
RX	O
*ondansetron	O
HCl	O
8	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
every	O
eight	O
(8)	O
hours	O
Disp	O
#*30	O
Tablet	O
Refills:*0	O
8.	O
biotin	O
1	O
mg	O
oral	O
DAILY	O
9.	O
Clobetasol	O
Propionate	O
0.05%	O
Cream	O
1	O
Appl	O
TP	O
BID:PRN	O
eczema	O
10.	O
Digestive	O
Advantage	O
(Bacillus	O
coagulans)	O
250	O
million	O
cell	O
oral	O
DAILY	O
11.	O
evening	O
primrose	O
oil	O
500	O
mg	O
oral	O
DAILY	O
12.	O
Glucosamine	O
1500	O
Complex	O
(glucosamine-chondroit-vit	O
C-Mn)	O
500-400	O
mg	O
oral	O
DAILY	O
13.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q24H	O
14.	O
HELD-	O
Ibuprofen	O
400	O
mg	O
PO	O
Q8H:PRN	O
Pain	O
-	O
Moderate	O
This	O
medication	O
was	O
held.	O
Do	O
not	O
restart	O
Ibuprofen	O
until	O
discussing	O
with	O
your	O
outpatient	O
doctors.	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
Pneumonia	B-Lower_respiratory_tract_infection
with	O
Pleural	O
Effusion	O
Follicular	O
Lymphoma	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
with	O
pneumonia	B-Lower_respiratory_tract_infection
and	O
had	O
fluid	O
around	O
your	O
lung	O
which	O
was	O
drained	O
with	O
a	O
chest	O
tube.	O
You	O
will	O
finish	O
a	O
course	O
of	O
antibiotics	O
as	O
an	O
outpatient.	O
You	O
did	O
developed	O
some	O
diarrhea	O
which	O
does	O
not	O
appear	O
to	O
be	O
due	O
to	O
an	O
infection.	O
It	O
is	O
likely	O
a	O
side	O
effect	O
of	O
medication.	O
Followup	O
Instructions:	O
___	O

